16305 36TH AVENUE N, MINNEAPOLIS, MN
Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Amended material disclosure
News, Material Contracts
Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Annual Report to Security Holders
Financial Results, Press Release
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities